Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

NCT04935359 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

511

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: NIS793
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals